Development of BET inhibitors as potential treatments for cancer: A search for structural diversity.

Autor: Hill MD; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA. Electronic address: matthew.hill@bms.com., Fang H; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Tokarski J; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Fanslau C; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Haarhoff Z; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Huang C; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Kramer M; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Menard K; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Monereau L; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Morrison J; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Ranasinghe A; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Shields EE; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Tye CK; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Westhouse R; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Everlof G; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Sheriff S; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Yan C; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Marsilio F; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Zhang L; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Zvyaga T; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Lee F; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Gavai AV; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA., Degnan AP; Bristol Myers Squibb Research and Development, 100 Binney St, Cambridge, MA 02142-1096, USA.
Jazyk: angličtina
Zdroj: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2021 Jul 15; Vol. 44, pp. 128108. Date of Electronic Publication: 2021 May 13.
DOI: 10.1016/j.bmcl.2021.128108
Abstrakt: We describe our efforts to identify structurally diverse leads in the triazole-containing N1-carboline series of bromodomain and extra-terminal inhibitors. Replacement of the N5 "cap" phenyl moiety with various heteroaryls, coupled with additional modifications to the carboline core, provided analogs with similar potency, improved pharmacokinetic properties, and increased solubility compared to our backup lead, BMS-986225 (2). Rapid SAR exploration was enabled by a convergent, synthetic route. These efforts provided a potent BET inhibitor, 3-fluoropyridyl 12, that demonstrated robust efficacy in a multiple myeloma mouse tumor model at 1 mg/kg.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: